Prostate cancer : hormonal treatment and treatment of advanced disease : proceedings from the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, Paris, June 22-24, 1994
Author(s)
Bibliographic Information
Prostate cancer : hormonal treatment and treatment of advanced disease : proceedings from the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, Paris, June 22-24, 1994
（European urology, v. 26 ; Supplement ; 1）
Karger, 1994
Available at 1 libraries
Note
Includes bibliographical references and indexes
Description and Table of Contents
Description
This special issue presents the proceedings of an international symposium held in Paris and attended by the world's experts in the field of prostate cancer. The contributions focus on the recent advances in the treatment of prostate cancer and show that several of the approaches to treatment discussed here are superseding the original gold standards of bilateral orchiectomy. Discussing the results of the most recent clinical trials in Europe and North America, this publication will undoubtedly prove to be of great value to urologists, andrologists and oncologists.
Table of Contents
- A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer, G.A. Dijkman et al
- the radiation therapy oncology group compiled by W.U. Shipley - a phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy alone for locally-advanced prostate cancer
- a multicentre trial of combined neoadjuvant androgen blockade with zoladex and flutamide prior to radical prostatectomy in prostate cancer, F.M.J. Debruyne et al
- on behalf of the international casodex investigators - update of clinical trials with the new anti-androgen, casodex (ICI 176,334), P. Iversen
- on behalf of all participating investigators et al - French multicentre trial comparing casodex (ICI 173,334) monotherapy with castration plus nilutamide in metastatic prostate cancer - a preliminary report, C. Chatelain
- on behalf of the international casodex investigators - tolerability and quality of life aspects with the anti-androgen casodex (ICI 176,334) as monotherapy for prostate cancer, C.J. Tyrrell
- strontium-89 (metastron) in the treatment of prostate cancer metastatic to bone, A.T. Porter
- a retrospective analysis of the cost effectiveness of treatment with metastron in patients with prostate cancer metastatic to bone, A.J.B. McEwan et al.
by "Nielsen BookData"